Assembly Biosciences (NASDAQ:ASMB) Shares Cross Above 200-Day Moving Average of $11.40

Assembly Biosciences, Inc. (NASDAQ:ASMBGet Free Report) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $11.40 and traded as high as $15.45. Assembly Biosciences shares last traded at $14.85, with a volume of 23,471 shares changing hands.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on ASMB shares. StockNews.com raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a report on Friday, May 10th. HC Wainwright reiterated a “neutral” rating on shares of Assembly Biosciences in a research report on Monday, April 1st.

Check Out Our Latest Report on Assembly Biosciences

Assembly Biosciences Price Performance

The company’s 50-day simple moving average is $13.48 and its 200-day simple moving average is $11.46.

Hedge Funds Weigh In On Assembly Biosciences

A hedge fund recently bought a new stake in Assembly Biosciences stock. Marquette Asset Management LLC acquired a new position in shares of Assembly Biosciences, Inc. (NASDAQ:ASMBFree Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 54,464 shares of the biopharmaceutical company’s stock, valued at approximately $45,000. Marquette Asset Management LLC owned 0.08% of Assembly Biosciences as of its most recent SEC filing. Hedge funds and other institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

(Get Free Report)

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.

See Also

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.